Clinical Scorecard: Factors Influencing the Severity of Pneumonitis Associated with Immune Checkpoint Inhibitors: Insights from Clinical, Radiological, and Laboratory Data in Real-World Settings

At a Glance

Key Highlights

• IIP incidence reported as 3-5% in clinical trials, higher in real-world settings
• Severity ranges from mild cough to fulminant respiratory failure
• Diagnosis requires integration of clinical evaluation, CT findings, and bronchoscopy when necessary
• Management typically involves withholding immunotherapy and administering systemic corticosteroids
• Data on clinical factors influencing severity remain limited

Guideline-Based Recommendations

Diagnosis

• Integrate clinical evaluation with thoracic CT findings
• Exclude alternative etiologies such as infection or tumor progression

Management

• Withhold immunotherapy
• Administer systemic corticosteroids based on severity grading

Monitoring & Follow-up

• Assess clinical course and radiologic resolution post-treatment

Risks

• Potential for serious and life-threatening toxicities

Patient & Prescribing Data

Adults aged ≥ 18 years with specific malignancies treated with ICIs

Comprehensive clinical and radiologic documentation is critical for effective management

Clinical Best Practices

• Conduct thorough baseline laboratory evaluations
• Perform bronchoscopy with BAL in moderate to severe cases
• Engage multidisciplinary teams for accurate diagnosis and management

References

• Clinical Trials and Real-World Data on IIP